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Lipid-raftPancreatic adenocarcinoma is often diagnosed when metastatic events have occurred. The early spread of
circulating cancer cells expressing the CD44 receptor may play a crucial role in this process. In this study,
we have investigated the cellular delivery ability and both in vitro and in vivo anti-tumoral activity of
liposomes conjugated with two different low molecular weight hyaluronic acids (HA 4.8 kDa and HA
12 kDa), the primary ligand of CD44, and containing a lipophilic gemcitabine (GEM) pro-drug. By confocal mi-
croscopy and ﬂow cytometry analyses, we demonstrate that the cellular uptake into a highly CD44-expressing
pancreatic adenocarcinoma cell line is higher with HA-conjugated (12 kDa>4.8 kDa) than non-conjugated
liposomes. Consistently, in vitro cytotoxic assays display an increased sensitivity towards GEM containing
HA-liposomes, compared to non-conjugated liposomes. Conversely, CD44 non-expressing normal cells
show a similar uptake and in vitro cytotoxicity with both HA-conjugated and non-conjugated liposomes.
Furthermore, we demonstrate that the HA-liposomes are taken up into the cells via lipid raft-mediated endo-
cytosis. All the liposome formulations containing GEM show a higher antitumoral activity than free GEM in a
mouse xenograft tumor model of human pancreatic adenocarcinoma. The 12 kDa HA-liposomes have the
strongest efﬁciency, while non-conjugated liposomes and the 4.8 kDa HA-liposomes are similarly active.
Taken together, our results provide a strong rationale for further development of HA-conjugated liposomes
to treat pancreatic adenocarcinoma.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive
and devastating human malignancies with a death-to-incidence ratio
of 0.99 and most of the patients presenting with metastatic disease at
the time of diagnosis. More than 75% of patients who undergo surgical
resection of small pancreatic tumors with clear surgical margins and no
evidence ofmetastasis, die frommetastasiswithin 5 years [1,2], aﬁnding
that is consistent with early spread. Recent studies have demonstratedDrug Technology, University of
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l rights reserved.that in a mouse model of PDAC cellular dissemination leading to metas-
tasis occurs prior to the formation of an identiﬁable primary tumor [3].
This behavior is associated with epithelial-to-mesenchymal transition
and with the establishment of circulating pancreatic cells which
maintain a mesenchymal phenotype and express CD44, a known
feature of cancer stem cells (CSCs) [4]. Evidence for the existence of
CSCs has been previously provided in primary human pancreatic
adenocarcinomas grown in immunocompromised mice [5]. All of
these ﬁndings suggest that CD44-targeted therapy may be a successful
approach for pancreatic adenocarcinoma in association to gemcitabine
(GEM), the ﬁrst-line chemotherapeutic agent since 1996 [6].
CD44 is a receptor binding hyaluronic acid (HA) with an important
role in CSC homing and adhesion [7]. HA binding-induced changes in
CD44 membrane localization and conformation trigger the association
and activation of multiple signal transduction molecules and proteases,
which support migration. This biological mechanism, together with the
observation that CD44 can internalize HA, indicates the possibility to
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been performed with HA–drug conjugates [8–10] or HA-targeted
nanoparticles (NP) [11–18]. Of the various NPs tested, liposome-based
NPs are among the best studied and clinically validated [19]. Further-
more, natural HA is a hydrophilic, non-immunogenic, biocompatible
and biodegradable polymer that provides a hydrophilic shield, similar
to polyethylene glycol (PEG), for the promotion of long blood circula-
tion [20].
In the present study, we investigated the cellular delivery ability
and the in vitro or in vivo anti-tumoral activity of liposomes which
contained lipophilic GEM pro-drugs and were conjugated with two
different MWHAs, on a highly CD44-expressing pancreatic adenocarci-
noma cell line and on CD44 non-expressing normal primary pancreatic
mesenchymal cells.
2. Materials and methods
2.1. Materials
Sodium hyaluronate (HA) of differentmolecular weights 4.8, 12 and
51 kDa was purchased from Lifecore Biomedical (Chaska, Minnesota).
All the phospholipids were provided by the Avanti Polar-Lipids distrib-
uted by Spectra 2000 (Rome, Italy). Gemcitabine (GEM, Jemta) was
from Sandoz, (Varese, Italy). The pro-drug 4-(N)-lauroyl-gemcitabine
(C12GEM) was synthesized as described by Immordino et al. [21] and
was used to retain gemcitabine into the liposome formulations.
Chlorpromazine hydrochloride (CPM), methyl-β-cyclodextrin (MβCD),
amiloride (AMIL), and nystatin (NYS) were purchased from Sigma-
Aldrich (Milan, Italy). Fluorescein-5-(and-6)-sulfonic acid trisodium
salt and Lissamine™ rhodamine B-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine triethylammonium salt (rhodamine-DHPE) were
provided by Invitrogen (Life Technologies, Monza, Italy).
2.2. Cell lines
MiaPaCa2 human PDAC cell line and VIT1 normal primary pancreatic
mesenchymal cells were grown in RPMI 1640 supplemented with
10% FBS, 2 mM of glutamine, and 50 μg/ml of gentamicin sulfate
(Gibco, Life Technologies, Milan). Cells were incubated at 37 °C with
5% CO2.
2.3. Liposome preparation
Liposomes composed of DPPC:Chol:PG, DPPC:Chol:PG/C12GEM
or DPPC:Chol:HA4.8kDa-DPPE/C12GEM, or DPPC:Chol:HA12kDa-DPPE/
C12GEM were prepared by thin lipid ﬁlm hydration and extrusion
method as reported [21]. Hyaluronated liposomes (HA-liposomes)
were obtained adding during liposome preparation a conjugate syn-
thesized by linking a phosphatidylethanolamine (1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine, DPPE) at the reducing end of
HA by reductive amination. Two HA-liposome formulations were
prepared containing, respectively, 4.8 and 12 kDa HA, which were fully
characterized for physico-chemical properties (unpublished results).
4.8 and 12 kDa HA-liposomes had a mean diameter of 154±3 and
192±2 nm, respectively. The zeta potential value decreasedwith the in-
creasing of the MW of the polymer and was about−30.7±0.7 mV for
4.8 kDa HA-liposomes and−43.1±0.9 for 12 kDa HA-liposomes.
2.4. Flow cytometry analysis of liposome uptake
MiaPaCa2 and VIT1 cells (3×105) were incubated with non-HA-
liposomes, 4.8 or 12 kDa HA-liposomes labeled with ﬂuorescein-5-
(and-6)-sulfonic acid trisodium salt for different incubation times, at
37 °C or 4 °C, as indicated in the legends to ﬁgures. In competitive bind-
ing or endocytic pathway assays, MiaPaCa2 cells were pre-treated with
increasing molar excess of free HA polymer (51 kDa), or increasingconcentrations of CPM, MβCD, AMIL, or NYS, respectively, for 1 h, then
treated with non-HA- or HA-liposomes for 1 h. The concentrations of
the inhibitors, indicated in the legend in Fig. 4, were chosen in a range
that was not toxic to the cells and was shown to determine a speciﬁc
uptake inhibition [22–25]. Then cells were washedwith PBS, trypsinized
for 6 min to dissociate the surface bound liposomes, resuspended in
300 μl of PBS and analyzed on a FACSCanto dual-laser cytometer
(Becton Dickinson, San Jose, CA). Flow cytometry data were gated
using the FlowJo software (TreeStar, Ashland, OR). Dead cells and de-
bris were excluded based upon forward scatter (FSC) and side scatter
(SSC) measurements. Liposome uptake mediated by HA was mea-
sured by calculating the ratio betweenmedian ﬂuorescence intensity
(RMFI) of cells treated with HA-liposomes and non-HA-liposomes
(fold-change).
2.5. Proliferation assays
Cells were plated in 96-well cell culture plates (4×103 cells/well)
and incubated overnight at 37 °C with 5% CO2. Then, cells were treat-
ed as the following: gemcitabine, C12GEM, or liposomes (DPPC:Chol:
PG liposome, DPPC:Chol:PG/C12GEM liposome, DPPC:Chol:HA4.8kDa-
DPPE/C12GEM liposome, and DPPC:Chol:HA12kDa-DPPE/C12GEM
liposome) and further incubated for 24 or 72 h. At the end of the treat-
ments, cell proliferationwas evaluated by Crystal Violet (Sigma-Aldrich)
staining and determined photometrically (A595 nm). Cell proliferation
was reported as a percentage relative to control cells grown in the
presence of an equal amount of the respective vehicle: H2O for GEM,
PBS for the liposome formulations or ethanol for C12GEM. Five inde-
pendent experiments were performed for each assay condition. DPPC:
Chol:PG liposomes non-containing C12GEM did not affect cell prolifer-
ation in our assay conditions (data not shown).
2.6. Confocal laser scanning microscopy
Liposome uptake has been evaluated inMiaPaCa2 andVIT1 cells. Cells
were seeded in 8-chamber polystyrene vessels (1.5×104 cells/well) and
grown overnight at 37 °C and 5% CO2 in culture medium. Hyaluronated
or non-hyaluronated liposomes labeled with ﬂuorescein-5-(and-6)-
sulfonic acid trisodium salt were added to the cells for 1 h, at 37° or
4 °C. To analyze the role of CD44 in liposome uptake, cells were also
pre-incubated with 100× molar excess of free high molecular weight
HA (51 kDa) for 1 h. At the end of the incubation periods, each well
was washed twice with PBS to remove the excess of vesicles, chambers
were removed and cells ﬁxed by 4% paraformaldehyde solution for
15 min. Then, each well was washed again with PBS. Cell membranes
were labeled with a 25 μg/ml rhodamine-DHPE solution for 10 min to
speciﬁcally highlight the cellular membranes. Then, cells were washed
twice with PBS. Cover glasses were positioned by using the antifading
ﬂuorescence mounting medium (Dako). The analysis was carried out
under a confocal laser scanning microscope Leica SP5 (magniﬁcation
40× with oil immersion objective) and samples visualized using the
488 nm excitation of argon laser for ﬂuorescein and 561 nm excitation
of HeNe laser for rhodamine.
2.7. In vivo studies
MiaPaCa2 cells (4×106 cells/mice) were s.c. injected into the nude
female mice (4 weeks of age, Harlan laboratories). One week after cell
inoculation, ten randomized animals chosen for each experimental
group, received solution vehicle (PBS), or 15 mg/kg of gemcitabine
(GEM), or liposomes DPPC:Chol:PG/C12GEM, or liposomes DPPC:
Chol:HA4.8kDa-DPPE/C12GEM, or liposomes DPPC:Chol:HA12kDa-DPPE/
C12GEM by intraperitoneal injection biweekly for 4 weeks. Tumor
volume and body mass were recorded biweekly for each animal.
Animals were killed at the end of the 4-week study period and the
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the Verona University Review Board.
2.8. Statistical analysis
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad
Prism 5. p valuesb0.05, 0.01 or 0.001 were indicated as *, ** or ***,
respectively.Fig. 1. (A) Histograms of the median ﬂuorescence intensity of MiaPaCa2 and VIT1 cells trea
ﬂuorescein. Values are the means (±SEM) of three independent experiments and are repo
HA- versus non-HA-liposomes (fold change). ***pb0.001. (B) Representative FACS histogram
4.8 kDa HA-, or 12 kDa HA-liposome formulations labeled with ﬂuorescein. (C) Confocal mic
(Lipo), 4.8 kDa HA-, or 12 kDa HA-liposome formulations labeled with ﬂuorescein. Green
labeled with rhodamine staining, and the overlay represents cellular association of liposom3. Results
3.1. Cellular uptake of ﬂuorescent HA-liposome formulations in PDAC cells
Several PDAC cell lines and the VIT1 normal primary pancreatic
mesenchymal cells were analyzed by ﬂow cytometry to determine the
relative surface expression levels of CD44 receptor (data not shown).
Among the PDAC cell lines, MiaPaCa2 showed the highest level ofted for 1 h at 37 °C or 4 °C, with 4.8 or 12 kDa HA-liposome formulations labeled with
rted as the ratio between relative median ﬂuorescence intensity (RMFI) obtained with
s of MiaPaCa2 and VIT1 cells untreated or treated for 1 h at 37 °C with non-HA (Lipo),
roscopy images of MiaPaCa2 and VIT1 cells treated for 1 h at 37 °C or 4 °C with non-HA
channel shows ﬂuorescein labeled liposomes, red channel shows cellular membranes
es.
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amount of the antigen (1.18±1 RMFI). These two cell types were
chosen for further analyses.
Cellular uptake of HA- or non-HA-liposomes labeled with ﬂuoresce-
inwas analyzed byﬂow cytometry. As shown in Fig. 1A andB, the ability
of MiaPaCa2 cells to incorporate both 4.8 or 12 kDa HA-liposome for-
mulations was signiﬁcantly higher than that of VIT1 cells, suggesting
that liposome uptake in MiaPaCa2 cells was mainly mediated by HA.
The incubation of HA-liposomes with cells at 4 °C, which inhibits all
the active energy-mediated processes, signiﬁcantly reduced the uptake
in MiaPaCa2 cells (Fig. 1A), suggesting that HA-liposomes entered cells
via an endocytic pathway. Cells treated as described above were also
analyzed by confocal laser scanner microscopy (Fig. 1C). MiaPaCa2
cells treated with ﬂuorescein-labeled HA-liposomes for 1 h at 37 °C
were strongly ﬂuorescent. In contrast, VIT1 cells showed a very low
signal, as well as MiaPaCa2 cells treated with non-targeted liposomes
or at 4 °C.
3.2. Inﬂuence of HA molecular weight on the cellular uptake of
HA-liposomes
To evaluate the inﬂuence of HA size on the efﬁcacy of targeted
delivery, we compared the 4.8 and 12 kDa HA-liposome uptake, rela-
tive to non-HA-liposomes, at different time points. Fig. 2A shows that
inMiaPaCa2 cells the speciﬁc cellular uptake occurred as early as 15 minFig. 2. Time-dependent median ﬂuorescence intensity of MiaPaCa2 (A) and VIT1 (B) cells tr
mulations labeled with ﬂuorescein. Values are the means of three independent experim
non-HA-liposomes. (C) Representative ﬂow cytometry analysis of MiaPaCa2 and VIT1 cell
the indicated time points. In VIT1 cells, similar results were obtained also with HA-liposomafter the beginning of the treatment with both 4.8 and 12 kDa
HA-liposome formulations and reached a peak at 1 or 6 h, respectively.
With longer times of incubations, up to 24 h, the presence into the
cells of 4.8 kDa HA-liposomes strongly decreased, while 12 kDa
HA-liposomes still remained at a high level. The HA-liposome speciﬁc
uptake in VIT1 cells was not signiﬁcant and did not increase with the
time (Fig. 2B). However, the non-speciﬁc incorporation of liposomes
in VIT1 cells, expressed as the median ﬂuorescence intensity of cells
treated with non-HA-liposomes, did increase with the time, while it
remained unchanged in MiaPaCa2 cells (Fig. 2C).3.3. Pathway of HA-liposome cellular uptake
In competitive binding experiments, pre-treatment of MiaPaCa2
cells with increasing amounts of free HA (51 kDa) signiﬁcantly de-
creased the HA-liposome uptake (Fig. 3A and B) for both the 4.8 and
12 kDa HA-liposomes. Instead, cells treated with non-HA-liposomes
did not change their ﬂuorescence after free HA pre-treatment. In
Fig. 3C, confocal microscopy analyses of MiaPaCa2 cells pre-treated
with free HA before HA-liposome incubation show very weak ﬂuores-
cent signals compared to HA-untreated cells. All of these ﬁndings indi-
cate that the free ligand competes with HA-liposomes for receptor
binding sites and, together with those described above, strongly sup-
port that CD44 mediates the interaction of cells with HA-liposomes.eated for 15 or 30 min, 1, 3, 6, 16, or 24 h at 37 °C with 4.8 or 12 kDa HA-liposome for-
ents and are reported as the ratio between ﬂuorescence obtained with HA- versus
s that incorporated non-HA-liposome (Lipo) formulations labeled with ﬂuorescein at
es.
Fig. 3. Effect of competitive ligand pre-treatment on cellular uptake of HA-liposomes in MiaPaCa2 cells. Cells were pre-incubated for 1 h with increasing molar excess of free HA
(51 kDa) and treated with HA-liposomes for 1 h. (A) Histograms of the median ﬂuorescence intensity of cells that incorporated 4.8 kDa HA- or 12 kDa HA-liposome formulations
labeled with ﬂuorescein, in the absence or presence of HA pre-treatment. Values are the means (±SEM) of three independent experiments. (*) pb0.001 HA+4.8 kDa HA vs.
4.8 kDa HA, (#) pb0.001 HA+12 kDa HA vs. 12 kDa HA. (B) Representative FACS histograms of MiaPaCa2 cells treated for 1 h at 37 °C with 4.8 kDa HA-, or 12 kDa
HA-liposome formulations labeled with ﬂuorescein, in the absence or presence of HA pre-treatment. (C) Confocal microscopy images of MiaPaCa2 cells treated for 1 h at 37 °C
with 4.8 kDa HA-, or 12 kDa HA-liposome formulations labeled with ﬂuorescein, in the absence or presence of HA pre-treatment. Green channel shows ﬂuorescein labeled lipo-
somes, red channel shows cellular membranes labeled with rhodamine staining, and the overlay represents cellular association of liposomes.
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transport, MiaPaCa2 cells were pre-treated with increasing amounts
of individual membrane entry inhibitors and then incubated with
4.8 or 12 kDa HA-liposome formulations. Flow cytometry analyses re-
vealed that methyl-β-cyclodextrin (MβCD), an inhibitor of lipid raft for-
mation by cholesterol depletion, strongly decreased the HA-liposome
uptake, in a concentration dependentmanner (Fig. 4A). In contrast, treat-
ment with chlorpromazine (CPM), nystatin (NYS), and amiloride (AMIL),
inhibitors of clathrin- or caveolae-mediated uptake or macropinocytosis,
respectively, did not signiﬁcantly alter the ﬂuorescence of the cells
compared to controls (Fig. 4B, C, and D). These results, together with
those described above, indicate that HA-liposomes enter the cells via a
lipid raft-mediated endocytosis, which depends on the binding of
HA-liposomes to the CD44 membrane receptor.3.4. In vitro cytotoxicity of liposome formulations against MiaPaCa2 cells
We next evaluated the cytotoxic activity of HA-liposomes containing
lipophilic GEM pro-drug. As shown in Fig. 5A, all of the liposome formu-
lations induced a concentration-dependent reduction of MiaPaCa2 cell
growth up to 500 nM and were more active than free GEM or C12GEM,
which displayed a similar activity. All the formulations at concentra-
tions higher than 500 nM did not further decrease cell proliferation,
consistent with our previous data obtained with GEM and variouspancreatic adenocarcinoma cell lines [26]. Liposomes conjugated with
HA showed a signiﬁcant higher anti-proliferative activity than the
non-conjugated ones and, according toﬂow cytometry and confocalmi-
croscopy data, 12 kDa HA-liposomes displayed a stronger effect than
4.8 kDa HA-liposomes. VIT1 cells were similarly sensitive to conjugated
or non-conjugated liposomes, freeGEMor C12GEM (Fig. 5B). Cell prolif-
eration was not signiﬁcantly altered by the presence of vehicle alone in
both cell lines (data not shown).3.5. Therapeutic responses to liposome formulations in nude mice bearing
MiaPaCa2 xenografts
The effect of HA-liposomes containing the lipophilic GEM pro-drug
was also investigated on growth inhibition of MiaPaCa2 cells s.c.
xenografted in nude mice. The examination of the volume–time curve
(Fig. 6A) reveals that the volume of tumors in mice treated with
12 kDa HA-liposomes increased at a signiﬁcant lower extent than that
in mice treated with 4.8 kDa HA liposomes or non-targeted liposomes.
During the experiment, mice body masses did not change, suggesting
that the treatments did not produce any apparent toxicity (Fig. 6B).
Fig. 6C shows that, at the end of the treatment period, free GEM did
not inhibit the tumormass growth in this drug-resistant pancreatic can-
cer xenograft model, while liposome formulations displayed different
levels of efﬁcacy. In particular, 12 kDa HA-liposomes determined a
Fig. 4. Effect of endocytosis inhibitors on cellular uptake of HA-liposomes in MiaPaCa2 cells. Cells were pre-incubated for 1 h with increasing amounts of methyl-β-cyclodextrin
(MβCD) to inhibit lipid raft-mediated endocytosis (A), chlorpromazine (CPM) to inhibit clathrin-mediated endocytosis (B), nystatin (NYS) to inhibit caveolae-speciﬁc endocytosis
(C), or amiloride (AMIL) to inhibitmacropinocytosis (D), and treatedwithHA-liposome formulations for 1 h. Control experiments of cell proliferation andmorphology demonstrated that
CPM, MβCD, AMIL, and NYS were not toxic at all concentrations used. Figure shows the histograms of the median ﬂuorescence intensity of cells that incorporated 4.8 kDa HA- or 12 kDa
HA-liposome formulations labeled with ﬂuorescein, in the absence or presence of endocytosis inhibitor pre-treatment. Values are themeans (±SEM) of three independent experiments.
(*) pb0.001 endocytosis inhibitors+4.8 kDa HA vs. 4.8 kDa HA, (#) pb0.001 endocytosis inhibitors+12 kDa HA vs. 12 kDa HA. Representative FACS histograms obtained with the
highest concentrations of the inhibitors are shown on the right side of the ﬁgure.
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HA liposomes or non-targeted liposomes and about 65% compared to
control or free GEM treatment.
4. Discussion
We show here for the ﬁrst time that a highly CD44-expressing
pancreatic adenocarcinoma cell line MiaPaCa2, presents an increased
uptake of liposomes carrying HA and an increased in vitro and in vivosensitivity towards GEM containing HA-liposomes, compared to
non-conjugated liposomes. Furthermore, we demonstrate that the
HA-liposomes are taken up into the cells via lipid raft-mediated
endocytosis, but not by clathrin- or caveolae-mediated uptake or
macropinocytosis.
The HA receptor CD44 is a known surface marker of cancer stem
cells (CSCs) in several human tumors, including pancreatic adenocarci-
noma [4,5]. CD44was ﬁrst identiﬁed on lymphocytes and found to have
cell adhesion and cell homing functions [27,28]. Thereafter, high CD44
Fig. 5. In vitro effect of liposome formulations on MiaPaCa2 (A) or VIT1 (B) cell growth.
Cells were seeded in 96-well plates, incubated overnight, and treated with increasing
concentrations ofGEM, C12GEM, non-HA (Lipo), 4.8 kDaHA-, or 12 kDaHA-liposome for-
mulations containingGEMpro-drug for 72 h (MiaPaCa2) or 24 h (VIT1). Cell proliferation
was determined using the Crystal Violet colorimetric assay as described in the Materials
and methods section. Values are the means of three independent experiments each
performed in triplicate. (#) signiﬁcant differences: GEM or C12GEM vs. Lipo, 4.8 kDa
HA-, or 12 kDa HA-liposomes; Lipo vs. 4.8 kDa HA-, or 12 kDa HA-liposomes; 4.8 kDa
HA- vs. 12 kDa HA-liposomes.
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and was shown to confer metastatic potential on non-metastasizing cell
lines [29–32]. Theories on the involvement of CD44 in tumorigenesis/
metastasis have been advanced and include production of autocrine
growth factors by tumor cells and intracellular locomotor signals
following ligand–CD44 interaction, CD44-mediated adhesion to the
extracellular matrix to invade hyaluronate rich tissues, and decreased
afﬁnity for surrounding hyaluronate deﬁcient cells leading to detach-
ment from the primary tumor mass [7,32].
Recently, it has been shown that metastasis associated with pan-
creatic adenocarcinoma derive from the primary tumor by cellular
dissemination of CSC-like cells occurring at early stages. Thus, the
overexpression of CD44 on pancreatic CSCs makes HA a potentially
interesting ligand for targeted therapy of pancreatic adenocarcinoma,
one of the most devastating human malignancies. Targeted therapy
has the advantage to minimize adverse effect by increasing drug con-
centration at the target site and decreasing it elsewhere in the body.
This effect can be accomplished as a result of the elevated target ex-
pression on tumor cells, the long circulation of the vehiculated drug,
often macromolecules or nanoparticles, and its access to the tumor
better than that to normal tissues (EPR: enhanced permeability andretention effect) [33–35]. HA exhibits a number of properties of a suc-
cessful targeting ligand including its non-immunogenic nature and
the presence of multiple functional groups available for chemical con-
jugation [36,37]. However, high MW HA (>103 kDa) is normally
cleared from the circulation by the hyaluronan receptor for endocyto-
sis (HARE) on liver sinusoidal endothelial cells [38,39]. To reduce HA
clearance from the blood, we employed short HA of 25 (4.8 kDa) and
63 (12 kDa) saccharides, respectively, taking advantage of CD44 ability
to interact with a minimum HA length of 6 to 8 saccharides [40,41].
Selecting HA oligosaccharides long enough to bind to CD44 but too
short to bind to the HARE receptor may permit an HA targeted carrier
to avoid elimination by the liver while maintaining targeting to cells
that overexpress CD44. Consistentwith those expectations, our ﬁndings
show that both 4.8 and12 kDaHA-liposomes displayhigh speciﬁcity to-
wards CD44-expressing MiaPaCa2 cells, while they are poorly internal-
ized by CD44 non-expressing VIT1 cells and at levels comparable to
those of non-HA liposomes. Flow cytometry analyses performed to eval-
uate the kinetics of liposome uptake reveal that 12 kDa HA-liposomes
are taken up by the cells at higher level than 4.8 kDa HA-liposomes,
suggesting a higher afﬁnity to CD44. This result is consistent with the
data reported by Mizrahy et al. [42]. The kinetics curves also show
that 12 kDa HA-liposomes remain longer into the cells than 4.8 kDa
HA-liposomes. Additional experiments will be necessary to clarify the
molecular mechanisms underlying the increased endocellular stability
of 12 kDa compared to 4.8 kDa HA-liposomes.
It is now well accepted that liposomes are internalized into the cells
through endocytosis, which can be clathrin-dependent or -independent
following liposome properties, which include charge and size, cell
types, andmolecular composition of the cell surface [43,44]. Targeting li-
posomes to a speciﬁc receptor present at the cell surface is expected to
enhance internalization activity and possibly modify the endocytic path-
way relative to non-targeted liposomes. CD44 has been recently shown
to use clathrin-independent endocytosis to enter cells [45]. Our confocal
microscopy and ﬂow cytometry analyses clearly show that the kinetics
of incorporation of liposomes through CD44-mediated mechanisms is
much faster than that occurring in the absence of CD44. However, the
increase with the time of the median ﬂuorescence intensity of the
CD44 non-expressing VIT1 cells treated with all liposome formulations
(Fig. 2C) suggests that non-speciﬁc liposome entrance into these
cells occurs, although at a very low rate. Consistent with data
reported by Qhattal et al. [23], we also demonstrate that the inhibi-
tion of lipid raft formation by cholesterol depletion completely elim-
inates HA-liposome internalization in MiaPaCa2 cells, while clathrin,
caveolae, or macropinocytosis are not involved in the uptake process. As
CD44 has been shown to localize in cholesterol-rich lipid raft [46], which
are responsible for its stability [47], wemay argue that cholesterol deple-
tion inhibits HA-liposome cellular uptake by inﬂuencing CD44 stability.
GEM (2′,2′-diﬂuoro-2′-deoxycytidine, dFdC) is a nucleoside ana-
logue of deoxycytidine used as a ﬁrst line therapy for pancreatic adeno-
carcinoma [6]. Most administered GEM undergoes rapid metabolism to
dFdU by deamination primarily in the blood, making GEM half-life as
short as 8–17 min in human plasma [48,49] and 9 min inmurine plasma
[50]. We have previously synthesized and encapsulated 4-(N)-acyl-GEM
derivatives into liposomes and demonstrated its longer plasma half-life
and higher in vitro cytotoxicity compared to the free drug [21]. Fur-
thermore, we have demonstrated that HA-lipoplexes are efﬁciently
transfected into CD44-expressing breast cancer cells [51]. Here, we
show that HA-targeted liposome formulations containing GEM have
an in vitro cytotoxic activity against CD44-expressing pancreatic adeno-
carcinoma cells higher than that of non-targeted liposomes or free GEM.
In contrast, CD44 non-expressing cells were similarly sensitive to
non-targeted or targeted liposomes. These ﬁndings are consistent with
those obtained in ﬂow cytometry and confocal microscopy analyses.
Our in vivo results obtained with a mouse xenograft tumor model
of human pancreatic adenocarcinoma show that all the liposome
formulations containing GEM were more efﬁcient than free GEM in
Fig. 6. Effect of liposome formulations on xenografts of MiaPaCa2 cells in nude mice. Cells were subcutaneously injected into female nude mice. After 1 week, i.p. injections with PBS
(solution vehicle), GEM, non-HA (Lipo), 4.8 kDa HA-, or 12 kDa HA-liposome formulations containing GEM pro-drug were carried out twice a week for 4 weeks, as described in the
Materials and methods section. (A) Values are the means of mice tumor volume measured 3 days after each injection. (#) signiﬁcant differences: PBS or GEM vs. Lipo, 4.8 kDa HA-,
or 12 kDa HA-liposomes; Lipo or 4.8 kDa HA-liposomes vs. 12 kDa HA-liposomes. (B) Values are the means of mice body mass measured 3 days after each injection. (C) Values are
the means of mice tumor mass (±SEM) measured after 8 injections. Signiﬁcant differences: PBS or GEM vs. Lipo or 4.8 kDa HA- liposomes, Lipo or 4.8 kDa HA-liposomes vs. 12 kDa
HA-liposomes, * pb0.05; GEM vs. 12 kDa HA-liposomes, ** pb0.01; PBS vs. 12 kDa HA-liposomes *** pb0.001.
1403E. Dalla Pozza et al. / Biochimica et Biophysica Acta 1828 (2013) 1396–1404inhibiting MiaPaCa2 cell growth, which mirror the results obtained in
the in vitro assay. However, while the 12 kDa HA-liposomes showed
the strongest antitumoral activity, non-HA-liposomes and the 4.8 kDa
HA-liposomes had a similar efﬁciency. To interpret this ﬁnding, we
should point out that non-HA-liposomes are not subjected to the
clearance from the blood via receptor-mediated mechanisms, such as
HARE. We may postulate that this advantage of non-HA-liposomes
could counterbalance the higher binding afﬁnity of HA-liposomes,
therefore rendering them, in an in vivo assay, as active as the 4.8 kDa
HA-liposomes, but still less active than the 12 kDa HA-liposomes. Our
report describes for the ﬁrst time in vivo experiments performed
using low MW HA-liposomes. Peer and Margalit [17,18] have reported
that liposomes charged with high MW HA and containing doxorubicin
or mitomycin C increase the antitumoral activity of the non-targeted
drug in various mice tumor models.
Taken together, our results provide a strong rationale for further
development of HA-conjugated liposomes, containing single or com-
bined drugs, to be used for the treatment of pancreatic adenocarcinoma.
Future studies will be addressed to evaluate the maximum tolerable
dose (MTD) for the liposomal formulations of GEM in order to evaluate
their therapeutic potential and the possible side effects.Acknowledgements
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